Pressione sanguigna ambulatoriale e indice di massa ventricolare sinistra nei bambini ipertesi.

Pressione sanguigna ambulatoriale e indice di massa ventricolare sinistra nei bambini ipertesi.

Per determinare se la pressione sanguigna ambulatoriale è più predittiva dell’ipertrofia ventricolare sinistra rispetto alla pressione sanguigna occasionale nei bambini ipertesi, sono stati analizzati i dati ecocardiografici e della pressione sanguigna ambulatoriale di 37 bambini ipertesi non trattati. La massa ventricolare sinistra è stata calcolata utilizzando l’equazione di Devereux, l’indice di massa ventricolare sinistro è stato calcolato come massa ventricolare sinistra (in grammi) / altezza (2,7) (in metri) e l’ipertrofia ventricolare sinistra è stata definita come indice di massa ventricolare sinistro> 51 g / m (2.7).

Sono stati calcolati la pressione sanguigna media, il carico di pressione sanguigna e l’indice di pressione sanguigna (pressione sanguigna media divisa per la pressione sanguigna ambulatoriale pediatrica 95 ° percentile). L’indice di massa ventricolare sinistro era fortemente correlato con l’indice della pressione arteriosa sistolica nelle 24 ore (r = 0,43, P = 0,008) ed era anche correlato con la pressione arteriosa sistolica nelle 24 ore (r = 0,34, P = 0,037), sangue sistolico nelle 24 ore carico di pressione (r = 0,38, P = 0,020), carico di pressione sanguigna sistolica sveglia (r = 0,37, P = 0,025), pressione sanguigna sistolica del sonno (r = 0,33, P = 0,048) e carico di pressione sanguigna sistolica del sonno (r = 0,38, P = 0,021).

L’indice di massa ventricolare sinistro non era correlato all’età, al peso, alla pressione sanguigna clinica o alla pressione sanguigna diastolica ambulatoriale. La prevalenza complessiva dell’ipertrofia ventricolare sinistra è stata del 27%. La prevalenza dell’ipertrofia ventricolare sinistra era del 47% (8 su 17) nei pazienti con carico della pressione arteriosa sistolica> 50% e indice della pressione arteriosa sistolica nelle 24 ore> 1,0, rispetto al 10% (2 su 20) nei pazienti senza entrambi i criteri (P = 0,015). Questi dati suggeriscono che il monitoraggio ambulatoriale della pressione arteriosa può essere utile per la valutazione clinica dei bambini ipertesi, identificando quelli ad alto rischio per la presenza di lesioni d’organo.

Un sistema di punteggio clinico per la selezione dei pazienti per il test di mutazione PTEN viene proposto sulla base di uno studio prospettico di 3042 probandi.

 

La sindrome di Cowden (CS) e la sindrome di Bannayan-Riley-Ruvalcaba sono alleliche, definite da mutazioni germinali di PTEN e collettivamente denominate sindrome tumorale da amartoma PTEN. Ad oggi, non ci sono criteri esistenti basati su ampie coorti di pazienti potenziali per selezionare i pazienti per il test di mutazione PTEN. Per affrontare questi problemi, abbiamo condotto uno studio prospettico multicentrico in cui sono stati accumulati 3042 probandi che soddisfacevano i criteri clinici rilassati della CS. La scansione della mutazione PTEN, inclusa l’analisi del promotore e dell’ampia delezione, è stata eseguita per tutti i soggetti.

Mutazioni patogene sono state identificate in 290 individui (9,5%). Per valutare il fenotipo clinico e il genotipo PTEN rispetto all’espressione proteica, abbiamo eseguito immunoblotting (PTEN, P-AKT1, P-MAPK1 / 2) per un sottogruppo di pazienti (n = 423). Al fine di ottenere una stima personalizzata della probabilità pretest di mutazione germinale PTEN, abbiamo sviluppato un modello di pratica clinica ottimizzato per identificare pazienti adulti e pediatrici. Per gli adulti, un punteggio semiquantitativo, il punteggio della Cleveland Clinic (CC), ha prodotto una stima ben calibrata della probabilità pre-test dello stato di PTEN.

Nel complesso, la diminuzione dell’espressione della proteina PTEN è correlata con lo stato di mutazione PTEN; la diminuzione dell’espressione della proteina PTEN era correlata con l’aumento del punteggio CC (p <0,001), ma non con i criteri del National Comprehensive Cancer Network (NCCN) (p = 0,11). Per i pazienti pediatrici, abbiamo identificato criteri altamente sensibili per guidare i test di mutazione PTEN, con caratteristiche fenotipiche distinte dall’ambiente adulto. Il nostro modello ha migliorato la sensibilità e il valore predittivo positivo per la mutazione germinale PTEN rispetto ai criteri NCCN 2010 in entrambe le coorti.

Pressione sanguigna ambulatoriale e indice di massa ventricolare sinistra nei bambini ipertesi.

Utilizzo del trasferimento dei compiti per aumentare rapidamente i servizi di trattamento dell’HIV: esperienze da Lusaka, Zambia.

 

L’Organizzazione Mondiale della Sanità sostiene il trasferimento dei compiti, il processo di delega delle funzioni di assistenza clinica da operatori sanitari più specializzati a operatori sanitari meno specializzati, come strategia per raggiungere gli Obiettivi di Sviluppo del Millennio delle Nazioni Unite. Tuttavia, c’è una carenza di letteratura che descrive il trasferimento di compiti nell’Africa subsahariana, dove i servizi per la terapia antiretrovirale (ART) sono aumentati rapidamente di fronte a crisi generalizzate delle risorse umane. Nell’ambito dell’espansione dei servizi ART a Lusaka, Zambia, abbiamo implementato un programma completo di trasferimento delle attività tra i fornitori di servizi sanitari esistenti e i lavoratori della comunità.

La formazione inizia con sessioni didattiche mirate a set di abilità specializzate. Segue un periodo intensivo di tutoraggio pratico, in cui i fornitori vengono associati ai formatori prima di lavorare in modo indipendente. Forniamo una valutazione della qualità continua utilizzando indicatori chiave della qualità dell’assistenza clinica in ogni sito. Le prestazioni del programma vengono riviste trimestralmente con il personale della clinica. Quando vengono identificati i problemi, i membri del personale della clinica progettano e implementano interventi specifici per affrontare aree mirate.

Rabbit Serum Sterile, trace-hemolized (56-84 days old)

31126-3 3L
EUR 694
Description: Produced from whole blood collected from young healthy rabbits (New Zealand White or Californian), 6+ months old. Pooled serum from male and female rabbits that are fasted prior to collection. The serum is processed, bottled, and stored at -20°C. Then the serum was thawed, pooled, passed through a 0.22-micron filter, bottled and returned to -20°C.

Rabbit PLASMA NS K2 EDTA YG LYO (3mL)

31144L-0 10x3ml
EUR 81.31

TAPI-0

2067-1
EUR 398

Antibody analysis - human >30 samples

8005-3 Custom service
EUR 113.8
Description: Antibody analysis - human >30 samples

RealScreen Pediatric FSH ELISA Kit

EL103-096 96T
EUR 1832

Human Plasma Progesterone standard (0 ng/ml)

1955-P4-00 10 ml Ask for price

Haptoglobin, (Phenotype 1-1) Human Plasma

7536-1
EUR 321

AGEs-BSA

KH001-A
EUR 870
Description: The AGEs-BSA is available in Europe and for worldwide shipping via Gentaur.

Human IgG-RF stripper/Adsorbent (1 ml, sufficient for stripping 50 samples of 100 ul human serum/plasma)

RFS-1 1 ml
EUR 103

ExoPure? 1.0 micron Immunobeads (Overall Exosome Isolation, plasma, urine, serum, 3 reactions)

M1039-3
EUR 436

Rabbit Complement 3-4 WK (1-mL)

31061-0 1mL
EUR 93.28

LysoPC(14:0/0:0)

HY-113123 5mg
EUR 142

pBI121 old Plasmid

PVT3002 2 ug
EUR 370

Albumin, Human Plasma

7546-1
EUR 240

Plasminogen, Human Plasma

7549-1
EUR 283

Prothrombin, Human Plasma

7684-1
EUR 180

Ceruloplasmin, Human Plasma

P1452-1
EUR 479

ExoPure? 0.4 micron Immunobeads (Overall Exosome Isolation, plasma, urine, serum)

M1038-3
EUR 436

Rabbit PLASMA NS EDTA 500mL

31141-1 500mL
EUR 261.84

Rabbit PLASMA S EDTA 500mL

31156-1 500mL
EUR 285.76

CK PLASMA NS EDTA 500mL

33141-1 500mL
EUR 184.63

CK PLASMA NS HEP 500mL

33142-1 500mL
EUR 184.63

Bovine PLASMA NS EDTA 500mL

37141-1 500mL
EUR 184.63

Bovine PLASMA NS HEP 500mL

37142-1 500mL
EUR 184.63

Pig PLASMA NS EDTA 500mL

39541-1 500mL
EUR 184.63

Pig PLASMA NS HEP 500mL

39542-1 500mL
EUR 184.63

Haptoglobin, Human Plasma (Mixed Type)

7535-1
EUR 158

Fibrinogen (plasminogen depleted), Human Plasma

7692-1
EUR 294

Antistreptolysin O (ASO), Human Plasma

P1453-1
EUR 207

Sheep AGEs ELISA Kit

ESA0009 96Tests
EUR 521

Mouse AGEs ELISA Kit

EMA0009 96Tests
EUR 521

Monkey AGEs ELISA Kit

EMKA0009 96Tests
EUR 521

Porcine AGEs ELISA Kit

EPA0009 96Tests
EUR 521

Rat AGEs ELISA Kit

ERA0009 96Tests
EUR 521

Rabbit AGEs ELISA Kit

ERTA0009 96Tests
EUR 521

Anserini AGEs ELISA Kit

EAA0009 96Tests
EUR 521

Goat AGEs ELISA Kit

EGTA0009 96Tests
EUR 521

Chicken AGEs ELISA Kit

ECKA0009 96Tests
EUR 521

Bovine AGEs ELISA Kit

EBA0009 96Tests
EUR 521

Human IgG1, Myeloma Plasma

20007-G1-1 1 mg
EUR 202

Human IgG2, Myeloma Plasma

20007-G2-1 1 mg
EUR 202

Human IgG3, Myeloma Plasma

20007-G3-1 1 mg
EUR 408

34011-0 Human Serum Off Clot Single Donor (1mL)

34011-1 1mL
EUR 68.81

Rabbit PLASMA NS W/ HEPARIN 500mL

31142-1 500mL
EUR 261.84

Rabbit PLASMA S NA CIT 500mL

31155-1 500mL
EUR 285.76

CK PLASMA NS S-CIT 500mL

33140-1 500mL
EUR 184.63

Bovine PLASMA NS S-CIT 500mL

37140-1 500mL
EUR 184.63

Pig PLASMA NS S-CIT 500mL

39540-1 500mL
EUR 184.63

Haptoglobin, (Phenotype 2-2) Human Plasma

7537-1
EUR 321

Alpha 2 HS Glycoprotein, Human Plasma

7548-1
EUR 272

Thrombin, Active, Bovine Plasma (Technical grade)

7591-1
EUR 120

Thrombin, Active, Bovine Plasma (High Activity)

7592-1
EUR 158

Rabbit BRAIN ACETONE POWDER VARISENS (1-g)

41170-0 1g
EUR 104.15

Heart Lysate (14 Days Old)

1401-14 0.1 mg
EUR 191
Description: Heart tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Lung Lysate (14 Days Old)

1402-14 0.1 mg
EUR 191
Description: Lung tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Lung Lysate (7 Days Old)

1402-7 0.1 mg
EUR 191
Description: Lung tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Brain Lysate (14 Days Old)

1403-14 0.1 mg
EUR 191
Description: Brain tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Brain Lysate (7 Days Old)

1403-7 0.1 mg
EUR 191
Description: Brain tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Liver Lysate (14 Days Old)

1404-14 0.1 mg
EUR 191
Description: Liver tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Liver Lysate (7 Days Old)

1404-7 0.1 mg
EUR 191
Description: Liver tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Kidney Lysate (14 Days Old)

1405-14 0.1 mg
EUR 191
Description: Kidney tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Kidney Lysate (7 Days Old)

1405-7 0.1 mg
EUR 191
Description: Kidney tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Spleen Lysate (14 Days Old)

1406-14 0.1 mg
EUR 191
Description: Spleen tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Spleen Lysate (7 Days Old)

1406-7 0.1 mg
EUR 191
Description: Spleen tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Thymus Lysate (14 Days Old)

1409-14 0.1 mg
EUR 191
Description: Thymus tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Thymus Lysate (7 Days Old)

1409-7 0.1 mg
EUR 191
Description: Thymus tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Stomach Lysate (14 Day Old)

1415-14 0.1 mg
EUR 191
Description: Stomach tissue lysate (14 Day Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Stomach Lysate (7 Day Old)

1415-7 0.1 mg
EUR 191
Description: Stomach tissue lysate (7 Day Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Skin Lysate (14 Days Old)

1419-14 0.1 mg
EUR 191
Description: Skin tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Skin Lysate (7 Days Old)

1419-7 0.1 mg
EUR 191
Description: Skin tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Eye Lysate (14 Days Old)

1420-14 0.1 mg
EUR 191
Description: Eye tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Eye Lysate (7 Days Old)

1420-7 0.1 mg
EUR 191
Description: Eye tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Yersinia Enterocolitica 0:3 Protein

abx061492-01ml 0.1 ml
EUR 551

Rabbit PLASMA NS NA CIT Y 500mL

31140-1 500mL
EUR 261.84

Rabbit PLASMA NS K2 EDTA Y 500mL

31144-1 500mL
EUR 261.84

Rabbit PLASMA NS K3 EDTA YG 500mL

31145-1 500mL
EUR 233.56

Guinea Pig AGEs ELISA Kit

EGA0009 96Tests
EUR 521

Mouse Aquaporin 0(AQP-0)ELISA Kit

GA-E0524MS-48T 48T
EUR 336

Mouse Aquaporin 0(AQP-0)ELISA Kit

GA-E0524MS-96T 96T
EUR 534

Rat Aquaporin 0(AQP-0)ELISA Kit

GA-E0572RT-48T 48T
EUR 336

Rat Aquaporin 0(AQP-0)ELISA Kit

GA-E0572RT-96T 96T
EUR 534

Human Aquaporin 0(AQP-0)ELISA Kit

GA-E1301HM-48T 48T
EUR 289

Human Aquaporin 0(AQP-0)ELISA Kit

GA-E1301HM-96T 96T
EUR 466

Human Aquaporin 0,AQP-0 ELISA Kit

201-12-1285 96 tests
EUR 440
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Rat Aquaporin 0(AQP-0)ELISA Kit

QY-E11080 96T
EUR 361

Mouse Aquaporin 0(AQP-0)ELISA Kit

QY-E20161 96T
EUR 361

Human Aquaporin 0(AQP-0)ELISA Kit

QY-E01463 96T
EUR 361

Rat Aquaporin 0,AQP-0 ELISA Kit

CN-01885R1 96T
EUR 471

Rat Aquaporin 0,AQP-0 ELISA Kit

CN-01885R2 48T
EUR 322

Mouse Aquaporin 0,AQP-0 ELISA Kit

CN-02762M1 96T
EUR 464

Mouse Aquaporin 0,AQP-0 ELISA Kit

CN-02762M2 48T
EUR 313

Human Aquaporin 0,AQP-0 ELISA Kit

CN-04417H1 96T
EUR 464

Dal 2005 al 2007, abbiamo formato 516 operatori sanitari nel trattamento dell’HIV negli adulti; 270 nel trattamento dell’HIV pediatrico; 341 in consulenza per l’adesione; 91 in un corso di “triage” per infermiere specializzato e 93 in un programma intensivo di tutoraggio clinico. La valutazione della qualità in corso ha dimostrato un miglioramento tra gli indicatori di qualità dell’assistenza clinica, nonostante i volumi di pazienti in rapida crescita. La nostra strategia di spostamento delle attività è stata progettata per soddisfare le attuali esigenze degli operatori sanitari e per sostenere le attività di scale-up ART. Sebbene questo approccio abbia avuto successo, sono urgentemente necessarie anche soluzioni a lungo termine alla crisi delle risorse umane per espandere il numero di fornitori e rallentare la migrazione del personale fuori dalla regione.